August 5, 2017. By Gordon Gibb.
Washington, DC: Towards the end of May plaintiffs embroiled in some 18,000 Xarelto lawsuits consolidated in multidistrict litigation were pushing back against a move by defendants Janssen Pharmaceuticals Inc. (Janssen, a division of Johnson & Johnson) and Bayer HealthCare Pharmaceuticals Inc. (Bayer) to escape claims that relied on allegations plaintiffs had previously dropped.Read [ Xarelto Seeking FDA Approval for Lower Dosage While Litigation Posturing Continues ]
July 8, 2017. By Gordon Gibb.
New Orleans, LA: The second bellwether Xarelto lawsuit in multidistrict litigation over allegations of Xarelto bleedout in association with the new age blood thinner has gone, like the first, to the defendant. While this may prove disappointing to litigants alleging the anticoagulant is unsafe, there are still two more bellwether trials to roll out later this year, with some 15,000 cases in the federal multidistrict litigation pipeline housed in New Orleans. Additional cases are percolating at the state level in Philadelphia.Read [ Second Bellwether Xarelto Lawsuit Goes to Defendant, All Eyes on Third ]
June 12, 2017. By Gordon Gibb.
New Orleans, LA: There is speculation that a bellwether Xarelto lawsuit, currently underway in the state of Louisiana, may end as the first bellwether concluded; with a verdict for the defense. However, legal commentator Tighe Wilhelmy of Velawcity notes that Louisiana’s ‘Learned Intermediary Doctrine Defense’ may not necessarily apply going forward to cases whose original jurisdictions fall outside the state of Louisiana.Read [ Forecasting the Xarelto Bellwether Trials ]
May 28, 2017. By Brenda Craig.
New Orleans, LA On May 30, 2017, a courtroom in New Orleans will hear testimony for another major bell weather case involving the controversial blood thinner drug Xarelto and the late Sharyn Orr from Kenner, Louisiana.Read [ Claims against Xarelto Due to Be Tested in Court Again ]
May 12, 2017. By Gordon Gibb.
New Orleans, LA: The long-anticipated first bellwether trial in multidistrict litigation for Xarelto side effects has gone to the defendants. Plaintiff Joseph Boudreaux’s trial commenced April 24 and all eyes were on the litigation as an indicator as to how other bellwether trials might go.Read [ First Xarelto Bellwether Trial Goes to the Defense ]
April 11, 2017. By Gordon Gibb.
Philadelphia, PA: As the Philadelphia Xarelto mass tort moves closer towards the bellwether trial stage, Xarelto principles Bayer AG and Janssen Pharmaceuticals have signaled that they want to know the identity of any third-party funders associated with Xarleto bleeding issue lawsuits. In other words, the defendants want to know how plaintiffs are funded.Read [ Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding ]
March 1, 2017. By Gordon Gibb.
New Orleans, LA: It could be mere co-incidence, but on the eve of the National Basketball Association (NBA) All Star Game that served to delay Xarelto bellwether trials by a month, the manufacturers of Xarelto chose to highlight an aging NBA all-star player who expounds upon the virtues of rivaroxaban (Xarelto) and professes to use it himself. As such, a visit to the official Xarelto website showcases the former All-American player, rather than the potential for a Xarelto bleeding issue.Read [ Plaintiffs Looking for a Slam Dunk in First Xarelto Bellwether Trial This Month ]
February 3, 2017. By Gordon Gibb.
New Orleans, LA: The maiden bellwether Xarelto lawsuit was originally scheduled to commence this month, an important event given that the number of Xarelto Bleeding Issue cases now exceeds 10,000.Read [ Xarelto Bellwether Pushed Back by NBA All-Star Game ]
January 6, 2017. By Gordon Gibb.
Orleans, LA: The massive Xarelto lawsuit portfolio, currently with almost 14,000 cases pending in multidistrict litigation, will see its first bellwether trial roll out in March with additional bellwethers slated for April and May. Plaintiffs allege that Xarelto, a blood thinner, triggered Xarelto bleeding complications without benefit of an available antidote to reverse the blood thinning properties of the anticoagulant.Read [ First Xarelto Bellwether Trial Due in March, Others to Follow in 2017 ]
December 5, 2016. By Gordon Gibb.
Washington, DC: In spite of assurances by the US Food and Drug Administration (FDA) that a recall of a monitoring device used to help determine the safety and effectiveness of Xarelto did not adversely affect outcomes, some 7,200 Xarelto lawsuits have been filed and consolidated in multidistrict litigation. The first bellwether Xarelto lawsuit is now only months away, scheduled for February of next year.Read [ FDA Assurances Likely Not Enough to Satisfy Xarelto Litigants ]